

Express Mail Label No.: EL 743 542 246 US

**UTILITY PATENT APPLICATION TRANSMITTAL**  
(Large Entity)

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

Docket No.

GH-50030-D1

**TO THE ASSISTANT COMMISSIONER FOR PATENTS**

**Box Patent Application**  
**Washington, DC 20231**

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**A METHOD OF IDENTIFYING AGONIST AND ANTAGONISTS FOR TUMOR NECROSIS RELATED RECEPTORS TR1 AND TR2**

and invented by:

**Michael R. Brigham-Burke and Peter R. Young**

**If a CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior Application No.: **09/072,993**

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No.: \_\_\_\_\_

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior Application No.: \_\_\_\_\_

Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having **27** pages and including the following:
  - a. ☒ Descriptive Title of the Invention
  - b. ☐ Cross References to Related Applications (if applicable)
  - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
  - d. ☐ Reference to Microfiche Appendix (if applicable)
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings (if drawings filed)
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure

**UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))*

**Docket No.**

**GH-50030-D1**

**Application Elements (Continued)**

3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☐ Formal Number of Sheets \_\_\_\_\_
- b. ☐ Informal Number of Sheets \_\_\_\_\_
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)* ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☒ Incorporation By Reference *(Usable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*
- a. ☒ Paper Copy
- b. ☒ Computer Readable Copy *(identical to paper copy)*
- c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☐ Assignment Papers *(cover sheet & document(s))*
9. ☐ 37 CFR 3.73(B) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☒ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgement Postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail *(Specify Label No.):* **EL 743 542 246 US**

**UTILITY PATENT APPLICATION TRANSMITTAL  
(Large Entity)***(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))*


Docket No.

GH-50030-D1

**Accompanying Application Parts (Continued)**15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*16. ☒ Additional Enclosures *(please identify below):***Copies of Assignment and Associate Power of Attorney****Fee Calculation and Transmittal****CLAIMS AS FILED**

FOR	FILED	ALLOWED	EXTRA	RATE	FEE
Total Claims	4	-20 =	0	x \$18.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$280.00	\$0.00
Basic Fee					<b>\$740.00</b>
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					<b>\$740.00</b>

☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **19-2387** as described below. A duplicate copy of this sheet is enclosed.☒ Charge the amount of **\$740.00** as filing fee.☐ Credit any overpayment.☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).☒ Customer No. **26130**  
SignatureDate: **October 25, 2001****Robert L. Andersen, Reg. No. 25,771  
Ratner & Prestia  
P.O. Box 980  
Valley Forge, PA 19482-0980  
(610) 407-0700  
(610) 407-0701 (FAX)**

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b> Applicant(s): <u>Michael Brigham-Burke, et al.</u>			<b>Docket No.</b>  <b>GH-50030-D1</b>
<b>Serial No.</b> <b>TO BE ASSIGNED</b>	<b>Filing Date</b> <b>HEREWITH</b>	<b>Examiner</b> <b>TO BE ASSIGNED</b>	<b>Group Art Unit</b> <b>TO BE ASSIGNED</b>
<b>Invention:</b>  <b>A METHOD OF IDENTIFYING AGONIST AND ANTAGONISTS FOR TUMOR NECROSIS RELATED RECEPTORS TR1 AND TR2</b>			
<p>I hereby certify that this <b><u>UTILITY TRANSMITTAL FORM WITH INDICATED ENCLOSURES</u></b> is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 on: <b><u>October 25, 2001.</u></b></p>			
<div style="text-align: center;"> <u><b>KATHLEEN LIBBY</b></u>          (Typed Or Printed Name o Person Mailing Correspondence)       </div> <div style="text-align: center;">           (Signature of Person Mailing Correspondence)       </div> <div style="text-align: center;"> <u><b>EL 743 542 246 US</b></u>          ("Express Mail" Mailing Label Number)       </div>			
<p><b>Note: Each paper must have its own certificate of mailing.</b></p>			